Search

everythinglearnresearchcommunity

for

Search:↓

CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Measuring minimal residual disease on day 15 helps identify high-risk leukemia patients.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Cosmetovigilance and clinical pharmacists can enhance safety in cosmetic treatments, especially for those with diabetes.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

All HPV vaccine studies should be registered and published to reduce reporting bias.

The gene therapy showed significant wound healing and was safe for treating severe RDEB.

Using 5-aminolevulinic acid photodynamic therapy for hair loss didn't increase hair growth but slightly reduced scalp oiliness, and it was safe with mild side effects.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

Insurers opposed ASCO's recommendation for a single cancer care pathway program.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Sonidegib and vismodegib have different side effects and reporting patterns.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.

Low-dose chemotherapy is safer, more effective, and cost-effective than surgery for treating bone lesions in children.

DALL-E 2 is only accurate for acne in pediatric dermatology and needs better data for other conditions.

Photodynamic therapy was effective in treating multiple scalp basal cell carcinomas with minimal side effects and good cosmetic results.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

A clinical nutrition program improved sensory and motor function in a 60-year-old with anti-MAG neuropathy.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

Laser-assisted drug delivery has shown improved treatment outcomes for skin conditions and has potential to reduce side effects and treatment time.

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.